MORE►
National Eye Institute
[Image: istockphoto]
Nanoscope Therapeutics Accelerates Sight-Restoring Drug Development with New Gene Therapy Manufacturing Partnership
by Kevin Cummings | Oct 18, 2022
Dallas-based Nanoscope Therapeutics is accelerating the development of therapies that could restore sight in patients with the help of a publicly traded firm. The retinal degenerative diseases-focused biotech company announced a new gene therapy manufacturing partnership with contract research organization Charles River Laboratories International.
by Alex Edwards |
Sep 14, 2021
The Bedford-based biotech will use the capital from the National Eye Institute of the National Institutes of Health to advance its gene therapy that treats age-related macular degeneration.
Earlier this summer, Nanoscope Therapeutics announced it successfully treated 11 patients who were blinded by advanced retinitis pigmentosa.
Earlier this summer, Nanoscope Therapeutics announced it successfully treated 11 patients who were blinded by advanced retinitis pigmentosa.
MORE►
by Alex Edwards |
Jun 1, 2020
DesignPlex Biomedical was given a royalty-free license by NASA to commercialize a new ventilator for coronavirus patients. Nanoscope Technologies got more than $2 million from the National Eye Institute to advance its gene therapy treatment.
MORE►
